Fisher Asset Management
DNLI icon

Fisher Asset Management’s Denali Therapeutics DNLI Stock Holding History

Fisher Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.1M Sell
2,414,162
-22,733
-0.9% -$467K 0.02% 222
2026
Q1 		$46.8M Sell
2,436,895
-152,508
-6% -$3.03M 0.02% 247
2025
Q4 		$42.8M Buy
2,589,403
+957,907
+59% +$16.2M 0.01% 250
2025
Q3 		$23.7M Buy
1,631,496
+115,505
+8% +$1.66M 0.01% 302
2025
Q2 		$21.2M Buy
1,515,991
+151,032
+11% +$2.13M 0.01% 309
2025
Q1 		$18.6M Buy
1,364,959
+572,460
+72% +$11M 0.01% 336
2024
Q4 		$16.2M Buy
792,499
+245,168
+45% +$6.28M 0.01% 374
2024
Q3 		$15.9M Buy
547,331
+69,223
+14% +$1.72M 0.01% 368
2024
Q2 		$11.1M Buy
478,108
+8,939
+2% +$172K ﹤0.01% 408
2024
Q1 		$9.63M Buy
+469,169
New +$8.82M ﹤0.01% 428

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Fisher Asset Management's DNLI Position: Q2 2026 in Review

Fisher Asset Management reduced its Denali Therapeutics (DNLI) stake by 0.93% in Q2 2026, selling an estimated $467K and leaving 2,414,162 shares worth $62.1M. The position accounts for 0.02% of the portfolio, ranked #222.

Fisher Asset Management first reported a position in DNLI in Q1 2024 and has held it in 10 quarters since. 112 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Fisher Asset Management held 2,414,162 shares of Denali Therapeutics worth $62.1M as of Q2 2026.
  • Fisher Asset Management sold 22,733 Denali Therapeutics shares in Q2 2026, an estimated $467K.
  • Denali Therapeutics made up 0.02% of Fisher Asset Management's portfolio in Q2 2026, its #222 holding.
  • Fisher Asset Management first reported a position in Denali Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 112 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.